Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
CardiovascularORALGeneric

EZETIMIBE AND SIMVASTATIN

EZETIMIBE; SIMVASTATIN

Standard Dose
10MG;10MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview EZETIMIBE AND SIMVASTATIN is listed in Drugs@FDA under application 211663 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient EZETIMIBE; SIMVASTATIN Form and strength TABLET;ORAL - 10MG;10MG Sponsor SCIEGEN PHARMS Submission history Latest submission status date: 2024-12-10 00:00:00.

Structured Monograph

Clinical summary

Approval overview EZETIMIBE AND SIMVASTATIN is listed in Drugs@FDA under application 211663 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient EZETIMIBE; SIMVASTATIN Form and strength TABLET;ORAL - 10MG;10MG Sponsor SCIEGEN PHARMS Submission history Latest submission status date: 2024-12-10 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
EZETIMIBE AND SIMVASTATIN (EZETIMIBE; SIMVASTATIN) | Drug Monograph | MedicHelpline